For myotwin, the convention offered a unique opportunity to present its platform of human-based cardiac tissue models in an international context and to engage directly with industry partners and experts. Discussions were particularly shaped by open dialogue on the future of drug development, strategies to reduce animal testing, and new partnership models.
Beyond the intensive business meetings, the convention also served as an inspiring forum: from keynotes by leading representatives of science, politics, and industry to personal stories such as that of actress Viola Davis, it became clear how much the sector is defined by innovation, collaboration, and humanity.
For myotwin, BIO International 2024 was not only a marketplace for partnerships but also a source of new energy and motivation. The company looks back on successful days in San Diego and forward with anticipation to the next steps that will emerge from the contacts established.
About myotwin
myotwin is a biotech company specializing in human–relevant, preclinical testing systems for the development of cardiovascular drugs. With its proprietary myoScreen platform, myotwin enables the simultaneous measurement of contraction force, tissue stiffness, calcium dynamics, and electrical activity—directly on human heart tissue.
As a next step, myotwin is developing myoAI, a digital twin of the heart muscle that uses artificial intelligence to predict the efficacy and toxicity of drugs. This is giving rise to a new generation of precise, data-driven drug development.
The Germany-based company works closely with research institutions, industry partners, and investors to advance innovative therapies for cardiovascular diseases more quickly and in a more targeted manner. For more information, visit www.myotwin.com.
Forward–looking statements
This communication may contain forward–looking statements based on current assumptions and forecasts made by myotwin’s management. Various known and unknown risks, uncertainties, and other factors could cause the actual results, financial position, development, or performance of the company to differ materially from the estimates given here. These factors include those described in myotwin’s public reports, which are available on the myotwin website at www.myotwin.com. The company assumes no obligation to update such forward-looking statements or to adapt them to future events or developments.
